
Camilla Krakstad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2478428/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Landscape of genomic alterations in cervical carcinomas. Nature, 2014, 506, 371-375.	27.8	708
2	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
3	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
4	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Molecular Cancer, 2010, 9, 135.	19.2	247
5	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
6	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
7	cAMP effector mechanisms. Novel twists for an â€~old' signaling system. FEBS Letters, 2003, 546, 121-126.	2.8	174
8	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics, 2016, 48, 848-855.	21.4	174
9	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
10	Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer, 2013, 49, 3431-3441.	2.8	123
11	Lack of Estrogen Receptor-α Is Associated with Epithelial–Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma. Clinical Cancer Research, 2013, 19, 1094-1105.	7.0	120
12	Ca2+/Calmodulin-dependent Protein Kinase II Is Required for Microcystin-induced Apoptosis. Journal of Biological Chemistry, 2002, 277, 2804-2811.	3.4	106
13	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
14	Preoperative tumor texture analysis on MRI predicts highâ€risk disease and reduced survival in endometrial cancer. Journal of Magnetic Resonance Imaging, 2018, 48, 1637-1647.	3.4	91
15	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer, 2014, 13, 223.	19.2	88
16	Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer, 2014, 50, 3003-3010.	2.8	73
17	Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers. PLoS ONE, 2013, 8, e54873.	2.5	70
18	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63

#	Article	IF	CITATIONS
19	Genetic overlap between endometriosis and endometrial cancer: evidence from crossâ€disease genetic correlation and GWAS metaâ€analyses. Cancer Medicine, 2018, 7, 1978-1987.	2.8	62
20	ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology, 2013, 26, 428-434.	5.5	61
21	Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome. British Journal of Cancer, 2012, 106, 1682-1688.	6.4	54
22	Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget, 2016, 7, 49289-49298.	1.8	53
23	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism, 2019, 7, 6.	5.0	51
24	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget, 2015, 6, 1327-1339.	1.8	50
25	Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . Cancer Research, 2014, 74, 852-861.	0.9	48
26	PTEN loss is a contextâ€dependent outcome determinant in obese and nonâ€obese endometrioid endometrial cancer patients. Molecular Oncology, 2015, 9, 1694-1703.	4.6	47
27	Wholeâ€Volume Tumor <scp>MRI</scp> Radiomics for Prognostic Modeling in Endometrial Cancer. Journal of Magnetic Resonance Imaging, 2021, 53, 928-937.	3.4	47
28	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
29	HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer, 2018, 118, 378-387.	6.4	43
30	cAMP protects neutrophils against TNF-α-induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). Journal of Leukocyte Biology, 2004, 76, 641-647.	3.3	41
31	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	2.9	40
32	Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification. Cancers, 2021, 13, 5848.	3.7	40
33	Annexinâ€A2 as predictor biomarker of recurrent disease in endometrial cancer. International Journal of Cancer, 2015, 136, 1863-1873.	5.1	39
34	Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology, 2017, 217, 432.e1-432.e17.	1.3	38
35	ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget, 2015, 6, 28440-28452.	1.8	37
36	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	1.0	37

#	Article	IF	CITATIONS
37	Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood, 2008, 111, 2866-2877.	1.4	35
38	High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition. Clinical Cancer Research, 2013, 19, 2331-2341.	7.0	35
39	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	5.1	35
40	Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Oncotarget, 2014, 5, 1052-1061.	1.8	35
41	Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer. PLoS ONE, 2014, 9, e90141.	2.5	34
42	High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated. PLoS ONE, 2012, 7, e52795.	2.5	34
43	Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. PLoS ONE, 2015, 10, e0135220.	2.5	33
44	Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica, 2018, 59, 1010-1017.	1.1	33
45	High visceral fat percentage is associated with poor outcome in endometrial cancer. Oncotarget, 2017, 8, 105184-105195.	1.8	33
46	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 980-987.	2.5	32
47	Patient-Derived Xenograft Models for Endometrial Cancer Research. International Journal of Molecular Sciences, 2018, 19, 2431.	4.1	32
48	High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology, 2020, 157, 260-267.	1.4	32
49	Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. Oncotarget, 2016, 7, 69844-69856.	1.8	30
50	Nostocyclopeptide-M1: A Potent, Nontoxic Inhibitor of the Hepatocyte Drug Transporters OATP1B3 and OATP1B1. Molecular Pharmaceutics, 2011, 8, 360-367.	4.6	29
51	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
52	High mRNA levels of 17β-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. Molecular and Cellular Endocrinology, 2017, 442, 51-57.	3.2	27
53	Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer, 2017, 117, 840-847.	6.4	26
54	Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer. International Journal of Molecular Sciences, 2018, 19, 3931.	4.1	26

#	Article	IF	CITATIONS
55	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Medicine, 2020, 17, e1003111.	8.4	25
56	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
57	Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. Gynecologic Oncology, 2015, 137, 529-537.	1.4	24
58	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
59	Automated segmentation of endometrial cancer on MR images using deep learning. Scientific Reports, 2021, 11, 179.	3.3	24
60	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 216-223.	2.5	22
61	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
62	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. Human Pathology, 2021, 109, 80-91.	2.0	22
63	Switch in FOXA1 Status Associates with Endometrial Cancer Progression. PLoS ONE, 2014, 9, e98069.	2.5	22
64	Blocking 17βâ€hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. Journal of Pathology, 2018, 244, 203-214.	4.5	21
65	Improving response to progestin treatment of low-grade endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 1811-1823.	2.5	21
66	Mitochondrial-Targeted Fatty Acid Analog Induces Apoptosis with Selective Loss of Mitochondrial Glutathione in Promyelocytic Leukemia Cells. Chemistry and Biology, 2003, 10, 609-618.	6.0	20
67	Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. Communications Medicine, 2021, 1, .	4.2	20
68	PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports, 2017, 7, 10240.	3.3	19
69	The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls. Current Topics in Medicinal Chemistry, 2011, 11, 1393-1405.	2.1	18
70	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
71	Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecologic Oncology, 2018, 148, 197-203.	1.4	18
72	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365.	3.8	18

#	Article	IF	CITATIONS
73	<i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. Clinical Cancer Research, 2019, 25, 334-345.	7.0	17
74	Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	3.3	16
75	Off-target effect of the Epac agonist 8-pCPT-2′-O-Me-cAMP on P2Y12 receptors in blood platelets. Biochemical and Biophysical Research Communications, 2013, 437, 603-608.	2.1	15
76	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
77	Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. European Radiology, 2020, 30, 2443-2453.	4.5	15
78	An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer. Journal of Clinical Medicine, 2021, 10, 538.	2.4	15
79	A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. British Journal of Cancer, 2021, 124, 1690-1698.	6.4	15
80	Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. Oncotarget, 2017, 8, 3881-3894.	1.8	15
81	Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology, 2017, 147, 672-677.	1.4	14
82	Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: a retrospective study. BMC Cancer, 2019, 19, 547.	2.6	14
83	PI3K Pathway in Gynecologic Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e218-e221.	3.8	14
84	MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer. Insights Into Imaging, 2022, 13, 1.	3.4	14
85	A radiogenomics application for prognostic profiling of endometrial cancer. Communications Biology, 2021, 4, 1363.	4.4	14
86	Blood steroids are associated with prognosis and fat distribution in endometrial cancer. Gynecologic Oncology, 2019, 152, 46-52.	1.4	13
87	Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas. Cancers, 2021, 13, 4551.	3.7	13
88	Blood Metabolites Associate with Prognosis in Endometrial Cancer. Metabolites, 2019, 9, 302.	2.9	12
89	Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. Oncotarget, 2017, 8, 109018-109026.	1.8	12
90	ldentification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLoS ONE, 2018, 13, e0206665.	2.5	11

#	Article	IF	CITATIONS
91	Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology, 2021, 160, 396-404.	1.4	11
92	Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. American Journal of Obstetrics and Gynecology, 2021, 225, 407.e1-407.e16.	1.3	11
93	High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling. International Journal of Molecular Sciences, 2022, 23, 373.	4.1	11
94	The prognostic value of preoperative FDG-PET/CT metabolic parameters in cervical cancer patients. European Journal of Hybrid Imaging, 2018, 2, .	1.5	10
95	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer, 2019, 120, 1037-1044.	6.4	10
96	Incorporating molecular profiling into endometrial cancer management requires prospective studies. International Journal of Gynecological Cancer, 2021, 31, 944-945.	2.5	10
97	Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers, 2020, 12, 370.	3.7	10
98	Development of an Image-Guided Orthotopic Xenograft Mouse Model of Endometrial Cancer with Controllable Estrogen Exposure. International Journal of Molecular Sciences, 2018, 19, 2547.	4.1	9
99	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
100	Asparaginaseâ€like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1695-1703.	2.3	9
101	Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer, 2020, 122, 1014-1022.	6.4	9
102	Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study. American Journal of Obstetrics and Gynecology, 2022, 226, 90.e1-90.e20.	1.3	9
103	Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. Oncotarget, 2017, 8, 106989-107001.	1.8	9
104	Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. Npj Genomic Medicine, 2021, 6, 82.	3.8	9
105	A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival. Cancers, 2021, 13, 5737.	3.7	9
106	Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer. Cancers, 2022, 14, 2372.	3.7	9
107	Introduction of Aromatic Ring-Containing Substituents in Cyclic Nucleotides Is Associated with Inhibition of Toxin Uptake by the Hepatocyte Transporters OATP 1B1 and 1B3. PLoS ONE, 2014, 9, e94926.	2.5	8
108	Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology, 2020, 156, 400-406.	1.4	8

#	Article	IF	CITATIONS
109	What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?. Insights Into Imaging, 2022, 13, .	3.4	8
110	InÂvivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica, 2018, 59, 497-505.	1.1	7
111	Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. PLoS ONE, 2019, 14, e0210585.	2.5	7
112	Nuclear upregulation of class I phosphoinositide 3-kinase p110β correlates with high 47S rRNA levels in cancer cells. Journal of Cell Science, 2021, 134, .	2.0	7
113	Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. Oncotarget, 2017, 8, 68530-68541.	1.8	7
114	Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology, 2012, 60, 516-519.	2.9	5
115	Type of vascular invasion in association with progress of endometrial cancer. Apmis, 2017, 125, 1084-1091.	2.0	5
116	Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human Pathology, 2019, 89, 90-98.	2.0	5
117	Imaging of Preclinical Endometrial Cancer Models for Monitoring Tumor Progression and Response to Targeted Therapy. Cancers, 2019, 11, 1885.	3.7	5
118	Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer. Journal of Translational Medicine, 2021, 19, 406.	4.4	5
119	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
120	Interobserver agreement and prognostic impact for MRI–based 2018 FIGO staging parameters in uterine cervical cancer. European Radiology, 2022, 32, 6444-6455.	4.5	5
121	Cancer awareness in the general population varies with sex, age and media coverage: A population-based survey with focus on gynecologic cancers. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 256, 25-31.	1.1	4
122	Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. Oncotarget, 2017, 8, 9696-9707.	1.8	4
123	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
124	Preoperative pelvic MRI and 2-[18F]FDG PET/CT for lymph node staging and prognostication in endometrial cancer—time to revisit current imaging guidelines?. European Radiology, 2023, 33, 221-232.	4.5	3
125	Serine/Threonine Protein Phosphatases in Apoptosis. , 2006, , 151-166.		2
126	Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathology Research and Practice, 2014, 210, 774-778.	2.3	0

#	Article	lF	CITATIONS
127	Abstract 4169: Loss of GPR30 expression identifies estrogen receptor positive endometrial carcinoma patients with poor outcome. , 2011, , .		0
128	Abstract 4604: Landscape of human and viral genomic alterations in cervical carcinomas , 2013, , .		0
129	Abstract 2875: ATAD2 overexpression indentifies aggressive endometrial carcinomas. , 2014, , .		0
130	Abstract 4692: Relationships between somatic genomic alterations, tumor stage and progression-free survival in cervical cancer. , 2014, , .		0
131	Abstract 4731: High level of nuclear heat-shock factor 1 is associated with aggressive disease and suggests targets for therapy in endometrial carcinoma. , 2014, , .		Ο
132	Abstract LB-120: HER2 as a potential predictive marker and target for therapy in cervical cancer. , 2015, ,		0
133	Abstract 1809: Expression of genes in the nuclear receptor superfamily defines a set of prognostic biomarkers in endometrial cancer. , 2018, , .		Ο
134	Abstract 4879: Poor outcome in hypoxic endometrial carcinoma is related to vascular density. , 2019, , .		0